Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Aug;131(9):1296-1305.
doi: 10.1111/1471-0528.17773. Epub 2024 Feb 6.

Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials

Antonio Cano  1 , Rossella E Nappi  2   3 , Nanette Santoro  4 , Petra Stute  5 , Martin Blogg  6 , Marci L English  7 , Antonia Morga  6 , Ludmila Scrine  6 , Emad Siddiqui  6 , Faith D Ottery  7
Affiliations
Free article
Randomized Controlled Trial

Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials

Antonio Cano et al. BJOG. 2024 Aug.
Free article

Abstract

Objective: To assess the effect of fezolinetant treatment on health-related quality of life using pooled data from SKYLIGHT 1 and 2 studies.

Design: Prespecified pooled analysis.

Setting: USA, Canada, Europe; 2019-2021.

Population: 1022 women aged ≥40 to ≤65 years with moderate-to-severe vasomotor symptoms (VMS; minimum average seven hot flushes/day), seeking treatment for VMS.

Methods: Women were randomised to 12-week double-blind treatment with once-daily placebo or fezolinetant 30 or 45 mg. Completers entered a 40-week, active extension (those receiving fezolinetant continued that dose; those receiving placebo re-randomised to fezolinetant received 30 or 45 mg).

Main outcome measures: Mean changes from baseline to weeks 4 and 12 on Menopause-Specific Quality of Life (MENQoL) total and domain scores, Work Productivity and Activity Impairment questionnaire specific to VMS (WPAI-VMS) domain scores, Patient Global Impression of Change in VMS (PGI-C VMS); percentages achieving PGI-C VMS of 'much better' (PGI-C VMS responders). Mean reduction was estimated using mixed model repeated measures analysis of covariance.

Results: Fezolinetant 45 mg mean reduction over placebo in MENQoL total score was -0.57 (95% confidence interval [CI] -0.75 to -0.39) at week 4 and -0.47 (95% CI -0.66 to -0.28) at week 12. Reductions were similar for 30 mg. MENQoL domain scores were also reduced and WPAI-VMS scores improved. Twice as many women receiving fezolinetant reported VMS were 'much better' than placebo based on PGI-C VMS assessment.

Conclusions: Fezolinetant treatment was associated with improvement in overall QoL, measured by MENQoL, and work productivity, measured by WPAI-VMS. A high proportion receiving fezolinetant felt VMS were 'much better' based on PGI-C VMS responder analysis.

Keywords: fezolinetant; health‐related quality of life; neurokinin 3 receptor antagonist; patient‐reported outcomes; vasomotor symptoms.

PubMed Disclaimer

References

REFERENCES

    1. Makara‐Studzińska M, Kryś‐Noszczyk KM, Wdowiak A, Kamińska M, Bakalczuk S, Bakalczuk G. Comparison of biopsychosocial functioning of women of different nationalities in the perimenopausal period. Prz Menopauzalny. 2014;13(6):339–343.
    1. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006;96(7):1226–1235.
    1. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, et al. Frequency and severity of vasomotor symptoms among peri‐ and postmenopausal women in the United States. Climacteric. 2008;11(1):32–43.
    1. Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, Dibonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013;20(5):518–524.
    1. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause‐specific questionnaire assessment in US population‐based study shows negative impact on health‐related quality of life. Maturitas. 2009;62(2):153–159.

Publication types

Grants and funding